ABSTRACT
Background Despite the monogenic autosomal dominant nature of Huntington’s disease (HD), the current research paradigm is still based on overt clinical phenotypes and does not address disease pathobiology and biomarkers that are evident decades before functional decline. A new research framework is needed to standardize clinical research and enable interventional studies earlier in the course of HD.
Methods The HD Regulatory Science Consortium (HD-RSC), a precompetitive Critical Path Institute initiative that includes 37 member organizations, created the Regulatory Science Forum working group (RSF), which includes industry and academic representatives. To generate a new evidenced-based HD Integrated Staging System (HD-ISS) using a formal consensus methodology, the RSF considered prognostic biomarkers, signs, and symptoms of HD, and performed empirical data analysis. We used observational data to calculate healthy-control-based landmark variable cut-offs for Stage classification and to internally validate the framework.
Findings The HD-ISS starts with Stage 0, which comprises individuals with ≥ 40 cytosine-adenine-guanine repeats (CAG) in the huntingtin gene (HTT), before detectable indications of disease. We concluded that detectable HD progression is verified with measurable indicators of underlying pathophysiology (Stage 1), proceeds to a detectable clinical phenotype (Stage 2), and continues to a decline in function (Stage 3). Operationally, individuals can be unambiguously classified into Stages 1-3 based on CAG-independent thresholds of landmark assessments. Both cross-sectional status and longitudinal HD-ISS Stage progress align with HD natural history, and Stage transitions accelerate as CAG increase.
Interpretation The HD-ISS encompasses the full course of HD starting at birth, defined by the presence of the genetic expansion. This new framework aims to standardize language for clinical research and its immediate use will enable further validation. The HD-ISS provides structure to harmonize clinical study populations and facilitates the clinical assessment of interventions earlier in HD to prevent or slow disease progression.
Funding CHDI Foundation Inc.
Competing Interest Statement
SJT received funding from the CHDI Foundation, the UK Dementia Research Institute that receives its funding from DRI Ltd., the UK Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK, and the Wellcome Trust (ref. 200181/Z/15/Z). SJT reports personal fees from F. Hoffmann La Roche Ltd, Annexon, PTC Therapeutics, Takeda Pharmaceuticals Ltd, Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc, Alphasights, Genentech, LoQus23 Therapeutics, Triplet Theraputics, Novartis, Atalanta, Spark Therapeutics, Horama, University College Irvine, and Guidepoint, outside the submitted work; in addition, SJT has a patent Application number 2105484.6 on the FAN1-MLH1 interaction and structural analogs licensed to Adrestia Therapeutics. SSc is a full-time employee of F. Hoffmann-La Roche, Ltd. ECG and CS are employees and receive salaries from CHDI Management. AM is a consultant to CHDI Management. BB is an employee of Novartis Pharmaceuticals. PK is Chief Scientific Officer and co-founder of VectorY. TAM received speaker honorariums from Abbvie and the International Parkinson and Movement Disorder Society; consultancies from CHDI Foundation/CHDI Management, Sunovion, Valeo Pharma, Roche, nQ Medical and Merz; advisory board from Abbvie, Biogen, Sunovion, Medtronic, and research funding from EU Joint Programme - Neurodegenerative Disease Research, uOBMRI, Roche, Ontario Research Fund, CIHR, MJFF, Parkinson Canada, PDF/PSG, LesLois Foundation, PSI Foundation, Parkinson Research Consortium and Brain Canada. JP and APM are full-time employees of Wave Life Sciences, LTD. CAR reports grants from CHDI Foundation, outside the submitted work; consultancies (current or recent) from HSG, Annexon, Mitoconix, NeuBase, NeuExcell, Roche/Genentech, Sage, Spark, Teva, uniQure, and Wave. MZ is an employee of Vaccinex, Inc.; in addition, MZ has a patent, "Use of semaphorin-4D binding molecules for treating neurodegenerative disorders," issued. KR, SSi, and ECT declare no conflict of interest. JDL reports grants from CHDI, during the conduct of the study; personal fees from F. Hoffmann-La Roche Ltd, uniQure biopharma B.V., Triplet Therapeutics, Inc., PTC Therapeutics Inc., Remix, Vaccinex Inc., and Wave Life Sciences USA Inc, outside the submitted work. CS received consultancy honorariums (unrelated to HD) from Pfizer, Kyowa Kirin, vTv Therapeutics, GW pharmaceuticals, Neuraly, Neuroderm, Green Valley Pharmaceuticals, and Pinteon Pharmaceuticals.
Funding Statement
CHDI Foundation Inc. provided financial support to the Critical Path Institute for the HD-RSC, including all working group efforts. The scope and activities of the working groups within the HD-RSC were agreed upon by the members of the HD-RSC Executive Committee. ECG and CS are employees of and receive salaries from CHDI Management. AM is a consultant to CHDI Management. The authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data from four studies were used during the conduct of this analysis: Enroll-HD (4th periodic data set; ClinicalTrials.gov Identifier: NCT01574053), IMAGE-HD, PREDICT-HD (ClinicalTrials.gov Identifier: NCT00051324), and TRACK-HD/Track-On. The IMAGE-HD and TRACK-HD/Track-On academic observational studies were not conducted in the US, therefore they are not registered in ClinicalTrials.gov and have not been issued a trial registration ID. An informed consent form (ICF) was signed by each participant in each study. The ICF outlines the reason for the study, study procedures, risk of participation, and consents to the broad use of the data for Huntington's disease research. Participant identifying information (date of birth, visit date, name, address, etc.) are not provided in any dataset. Each participating study site received approval after submitting the study protocol and ICF to their local/regional ethics board prior to the start of participant recruitment. Some ethics committees re-review the study annually, others only upon protocol amendments. Comments from the ethics committees are reviewed and changes to the ICF made where appropriate. All ethics approval letters are maintained on file by the study sponsor. All signed ICFs are maintained at the study site.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* joint first authors
Data Availability
We used four publicly available data sets: Enroll-HD (4th periodic data set), IMAGE-HD, PREDICT-HD, and TRACK-HD. Contact info@chdifoundation.org for more information regarding data access.
